<DOC>
	<DOCNO>NCT01412385</DOCNO>
	<brief_summary>The purpose study develop 20 % subcutaneous immunoglobulin treatment option patient primary immunodeficiency ( PID ) diseases .</brief_summary>
	<brief_title>Immune Globulin Subcutaenous ( Human ) , 20 %</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Subject must document diagnosis form primary humoral immunodeficiency involve antibody formation require gammaglobulin replacement , define accord IUIS Scientific Committee 2009 , diagnostic criterion accord Conley ME , Notarangelo LD , Etzioni A . Diagnostic criterion primary immunodeficiency . Clin Immunol 1999 ; 93:190197 . The diagnosis must confirm Medical Director prior enrollment . Subject 2 year old time screen Written informed consent obtain either subject subject 's legally authorize representative prior studyrelated procedure study product administration Subject receive consistent dose IgG period least 3 month prior screen average minimum dose interval equivalent 300 mg/kg body weight ( BW ) /4 week maximum dose equivalent 1.0 gram/kg BW/4 week dose frequency follow : 1. intravenously ( IV ) mean interval approximately 3 4 week 2. subcutaneously ( SC ) mean interval approximately 1 2 week Subject serum trough level IgG &gt; 5 g/L screen Subject serious bacterial infection within 3 month prior screen Subject willing able comply requirement protocol Subject know history positive screen one following : hepatitis B surface antigen ( HBsAg ) , polymerase chain reaction ( PCR ) hepatitis C virus ( HCV ) , PCR human immunodeficiency virus ( HIV ) Type 1/2 Abnormal laboratory value screen meet one follow criterion ( abnormal test may repeat determine persistent ) : 1 . Persistent alanine aminotransferase ( ALT ) aspartate amino transferase ( AST ) &gt; 2.5 time upper limit normal test laboratory 2 . Persistent severe neutropenia ( define absolute neutrophil count [ ANC ] &lt; = 500 /mm3 ) Subject creatinine clearance ( CLcr ) value &lt; 60 % normal age gender Subject diagnose malignancy ( adequately treat basal cell squamous cell carcinoma skin carcinoma situ cervix ) , unless diseasefree period prior screen exceeds 5 year Subject receive anticoagulation therapy history thrombotic episode ( include deep vein thrombosis , myocardial infarction , cerebrovascular accident , pulmonary embolism ) within 12 month prior screen history thrombophilia Subject abnormal protein loss ( protein lose enteropathy , nephrotic syndrome ) Subject anemia would preclude phlebotomy laboratory study accord standard practice site Subject ongoing history hypersensitivity persistent reaction ( urticaria , breathe difficulty , severe hypotension , anaphylaxis ) follow IV immunoglobulin , SC immunoglobulin , and/or Immune Serum Globulin ( ISG ) infusion Subject immunoglobulin A ( IgA ) deficiency ( IgA less 0.07g/L ) know anti IgA antibody Subject preventative ( prophylactic ) systemic antibacterial antibiotic dose sufficient treat prevent bacterial infection , stop antibiotic time screen Subject active infection receive antibiotic therapy treatment infection time screen Subject bleed disorder platelet count less 20,000/Î¼L , , opinion investigator , would significant risk increase bleed bruise result subcutaneous therapy Subject total protein &gt; 9 g/dL myeloma , macroglobulinemia ( IgM ) paraproteinemia Women childbearing potential meeting one follow criterion 1. subject present positive pregnancy test 2. subject breast feeding 3. subject intend begin nurse course study 4. subject agree employ adequate birthcontrol measure ( e.g . intrauterine device , diaphragm condom [ male partner ] spermicidal jelly foam , birth control pills/patches ) throughout course study Subject participate another clinical study expose investigational product ( IP ) device within 30 day prior study enrollment ( exception : treatment immunoglobulin prestudy ) Subject schedule participate another ( nonBaxter ) nonobservational ( interventional ) clinical study involve IP device course study Subject severe dermatitis would preclude adequate site safe product administration</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>